title: Reduction of the washout time between natalizumab and fingolimod.
authors.forename: Jérôme
authors.initials: J
authors.lastname: de Seze
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Ongagna
authors.forename: Nicolas
authors.initials: N
authors.lastname: Collongues
authors.forename: Christophe
authors.initials: C
authors.lastname: Zaenker
authors.forename: Sylvie
authors.initials: S
authors.lastname: Courtois
authors.forename: Marie
authors.initials: M
authors.lastname: Fleury
authors.forename: Aurélien
authors.initials: A
authors.lastname: Benoilid
authors.forename: Jean-Baptiste
authors.initials: JB
authors.lastname: Chanson
authors.forename: Frédéric
authors.initials: F
authors.lastname: Blanc
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D005260:Female; D000068876:Fingolimod Hydrochloride; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy*; D000069442:Natalizumab; D011409:Propylene Glycols / Q000008:administration & dosage*; D013110:Sphingosine / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D000069442:Natalizumab; D011409:Propylene Glycols; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine